Publications found:
36,694
Sort by:
Prostate Cancer – Pipeline Insight, 2020
US$ 5,000.00
This report can be delivered to the clients within 5 Business days DelveInsight’s, “Prostate Cancer – Pipeline Insight, 2020,” report provides comprehensive insights about 900+ companies and 900+ pi...
November 2020
350 pages
Severe Hypoglycemia – Pipeline Insight, 2020
US$ 2,500.00
This report can be delivered to the clients within 48-72 Hours DelveInsight’s, “Severe Hypoglycemia – Pipeline Insight, 2020,” report provides comprehensive insights about 30+ companies and 30+ pipe...
November 2020
80 pages
Spinocerebellar Ataxias - Pipeline Insight, 2020
US$ 1,500.00
This report can be delivered to the clients within 24-48 Hours DelveInsight’s, “Spinocerebellar Ataxias – Pipeline Insight, 2020,” report provides comprehensive insights about 3+ companies and 3+ pi...
November 2020
50 pages
NF-kappa B Inhibitors – Pipeline Insight, 2020
US$ 2,500.00
This report can be delivered to the clients within 72 Hours DelveInsight’s, “NF-kappa B Inhibitors – Pipeline Insight, 2020,” report provides comprehensive insights about 90+ companies and 90+ pipel...
November 2020
150 pages
Acute Radiation Syndrome – Pipeline Insight, 2020
US$ 1,500.00
This report can be delivered to the clients within 48-72 Hours DelveInsight’s, “Acute Radiation Syndrome – Pipeline Insight, 2020,” report provides comprehensive insights about 10+ companies and 10+...
November 2020
60 pages
Global HIV Drugs Market By Medication Class (Multi-class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors (NRTIs), Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs), Protease Inhibitors (PIs), Entry Inhibitors, and HIV Integrase Strand Transfer Inhibitors): Opportunity Analysis and Industry Forecast, 2020–2027
US$ 5,243.00
The global HIV drugs market was valued at $30,891.48 million in 2019, and is expected to reach $36,495.47 million by 2027, registering a CAGR of 3.8% from 2020 to 2027. Human immunodeficiency virus (H...
November 2020
237 pages
Amyloidosis R&D Pipeline Analysis Report, Q4 2020
US$ 1,529.00
Amyloidosis Pipeline Overview The Q4 Amyloidosis pipeline report is part of the VPA Metabolic Disorder disease pipeline service. This quarterly review describes the pipeline of drugs under development...
October 2020
151 pages
Anaphylaxis R&D Pipeline Analysis Report, Q4 2020
US$ 1,529.00
Anaphylaxis Pipeline Overview The Q4 Anaphylaxis pipeline report is part of the VPA immunology disease pipeline service. This quarterly review describes the pipeline of drugs under development for Ana...
October 2020
52 pages
Anthrax R&D Pipeline Analysis Report, Q4 2020
US$ 1,529.00
Anthrax Pipeline Overview The Q4 Anthrax pipeline report is part of the VPA 110 Infectious Disease pipeline service. This quarterly review describes the pipeline of drugs under development for Anthrax...
October 2020
116 pages
Aspergillosis R&D Pipeline Analysis Report, Q4 2020
US$ 1,529.00
Aspergillosis Pipeline Overview The Q4 Aspergillosis pipeline report is part of the VPA 110 Infectious Disease pipeline service. This quarterly review describes the pipeline of drugs under development...
October 2020
135 pages
Bacterial Vaginosis R&D Pipeline Analysis Report, Q4 2020
US$ 1,529.00
Bacterial Vaginosis Pipeline Overview The Q4 Bacterial Vaginosis pipeline report is part of the VPA 110 Infectious Disease pipeline service. This quarterly review describes the pipeline of drugs under...
October 2020
76 pages
Birch Pollen Allergy R&D Pipeline Analysis Report, Q4 2020
US$ 1,529.00
Birch Pollen Allergy Pipeline Overview The Q4 Birch Pollen Allergy pipeline report is part of the VPA immunology disease pipeline service. This quarterly review describes the pipeline of drugs under d...
October 2020
41 pages
Botulism R&D Pipeline Analysis Report, Q4 2020
US$ 1,529.00
Botulism Pipeline Overview The Q4 Botulism pipeline report is part of the VPA 110 Infectious Disease pipeline service. This quarterly review describes the pipeline of drugs under development for Botul...
October 2020
41 pages
Candidiasis R&D Pipeline Analysis Report, Q4 2020
US$ 1,979.00
Candidiasis Pipeline Overview The Q4 Candidiasis pipeline report is part of the VPA 110 Infectious Disease pipeline service. This quarterly review describes the pipeline of drugs under development for...
October 2020
210 pages
Cat Allergy R&D Pipeline Analysis Report, Q4 2020
US$ 1,529.00
Cat Allergy Pipeline Overview The Q4 Cat Allergy pipeline report is part of the VPA immunology disease pipeline service. This quarterly review describes the pipeline of drugs under development for Cat...
October 2020
42 pages
Chikungunya Fever R&D Pipeline Analysis Report, Q4 2020
US$ 1,979.00
Chikungunya Fever Pipeline Overview The Q4 Chikungunya Fever pipeline report is part of the VPA 110 Infectious Disease pipeline service. This quarterly review describes the pipeline of drugs under dev...
October 2020
138 pages
Chlamydia Infections R&D Pipeline Analysis Report, Q4 2020
US$ 1,529.00
Chlamydia Infections Pipeline Overview The Q4 Chlamydia Infections pipeline report is part of the VPA 110 Infectious Disease pipeline service. This quarterly review describes the pipeline of drugs und...
October 2020
72 pages
Cholera R&D Pipeline Analysis Report, Q4 2020
US$ 1,529.00
Cholera Pipeline Overview The Q4 Cholera pipeline report is part of the VPA 110 Infectious Disease pipeline service. This quarterly review describes the pipeline of drugs under development for Cholera...
October 2020
51 pages
Coccidioidomycosis R&D Pipeline Analysis Report, Q4 2020
US$ 1,529.00
Coccidioidomycosis Pipeline Overview The Q4 Coccidioidomycosis pipeline report is part of the VPA 110 Infectious Disease pipeline service. This quarterly review describes the pipeline of drugs under d...
October 2020
51 pages
Cryptococcosis R&D Pipeline Analysis Report, Q4 2020
US$ 1,529.00
Cryptococcosis Pipeline Overview The Q4 Cryptococcosis pipeline report is part of the VPA 110 Infectious Disease pipeline service. This quarterly review describes the pipeline of drugs under developme...
October 2020
62 pages
Cryptosporidiosis R&D Pipeline Analysis Report, Q4 2020
US$ 1,529.00
Cryptosporidiosis Pipeline Overview The Q4 Cryptosporidiosis pipeline report is part of the VPA 110 Infectious Disease pipeline service. This quarterly review describes the pipeline of drugs under dev...
October 2020
35 pages
Dengue Fever R&D Pipeline Analysis Report, Q4 2020
US$ 1,979.00
Dengue Fever Pipeline Overview The Q4 Dengue Fever pipeline report is part of the VPA 110 Infectious Disease pipeline service. This quarterly review describes the pipeline of drugs under development f...
October 2020
163 pages
Diabetic Neuropathy R&D Pipeline Analysis Report, Q4 2020
US$ 1,529.00
Diabetic Neuropathy Pipeline Overview The Q4 Diabetic Neuropathy pipeline report is part of the VPA Metabolic Disorder disease pipeline service. This quarterly review describes the pipeline of drugs u...
October 2020
142 pages
Diphtheria R&D Pipeline Analysis Report, Q4 2020
US$ 1,529.00
Diphtheria Pipeline Overview The Q4 Diphtheria pipeline report is part of the VPA 110 Infectious Disease pipeline service. This quarterly review describes the pipeline of drugs under development for D...
October 2020
92 pages
Genital Herpes R&D Pipeline Analysis Report, Q4 2020
US$ 1,529.00
Genital Herpes Pipeline Overview The Q4 Genital Herpes pipeline report is part of the VPA 110 Infectious Disease pipeline service. This quarterly review describes the pipeline of drugs under developme...
October 2020
128 pages
Gonorrhea R&D Pipeline Analysis Report, Q4 2020
US$ 1,529.00
Gonorrhea Pipeline Overview The Q4 Gonorrhea pipeline report is part of the VPA 110 Infectious Disease pipeline service. This quarterly review describes the pipeline of drugs under development for Gon...
October 2020
94 pages
Grass Pollen Allergy R&D Pipeline Analysis Report, Q4 2020
US$ 1,529.00
Grass Pollen Allergy Pipeline Overview The Q4 Grass Pollen Allergy pipeline report is part of the VPA immunology disease pipeline service. This quarterly review describes the pipeline of drugs under d...
October 2020
62 pages
Hepatitis A R&D Pipeline Analysis Report, Q4 2020
US$ 1,529.00
Hepatitis A Pipeline Overview The Q4 Hepatitis A pipeline report is part of the VPA 110 Infectious Disease pipeline service. This quarterly review describes the pipeline of drugs under development for...
October 2020
57 pages
Hepatitis C (HCV) R&D Pipeline Analysis Report, Q4 2020
US$ 1,979.00
Hepatitis C (HCV) Pipeline Overview The Q4 Hepatitis C (HCV) pipeline report is part of the VPA 110 Infectious Disease pipeline service. This quarterly review describes the pipeline of drugs under dev...
October 2020
210 pages
Hepatitis D R&D Pipeline Analysis Report, Q4 2020
US$ 1,529.00
Hepatitis D Pipeline Overview The Q4 Hepatitis D pipeline report is part of the VPA 110 Infectious Disease pipeline service. This quarterly review describes the pipeline of drugs under development for...
October 2020
62 pages
Hereditary Angioedema R&D Pipeline Analysis Report, Q4 2020
US$ 1,529.00
Hereditary Angioedema Pipeline Overview The Q4 Hereditary Angioedema pipeline report is part of the VPA immunology disease pipeline service. This quarterly review describes the pipeline of drugs under...
October 2020
104 pages
